TY - JOUR
T1 - Comparative survival of elderly renal transplant recipients with a living donor versus a deceased donor
T2 - A retrospective single center observational study
AU - Tegzess, Erzsi
AU - Gomes Neto, Antonio W
AU - Pol, Robert A
AU - de Boer, Silke E
AU - Peters-Sengers, Hessel
AU - Sanders, Jan-Stephan F
AU - Berger, Stefan P
N1 - This article is protected by copyright. All rights reserved.
PY - 2021/12
Y1 - 2021/12
N2 - Increasing numbers of elderly (>= 65 years) patients are listed for kidney transplantation. This study compares the survival outcome between living (LDK), regularly allocated (ETKAS), and Eurotransplant Senior Program (ESP) donor kidneys in elderly recipients. This is a single-center retrospective cohort study of elderly kidney transplant recipients transplanted between 2005 and 2017. Primary outcome measures were nondeath-censored graft, death-censored graft, and patient survival. In total, 348 patients were transplanted, 109 recipients (31.3%) received an LDK, 100 (28.7%) an ETKAS, and 139 (40%) an ESP kidney. 62.5% were male, and median age was 68 years. LDK recipients had significantly better 5-year nondeath-censored graft survival compared with ETKAS and ESP (resp. 71.0% vs. 66.1% vs. 55.6%, P = 0.047). Death-censored graft survival after 1 year was significantly better in LDK recipients (99.1%) (ETKAS 90.8%; ESP 87.7%, P < 0.001). After 5 years, the difference remained significant (P < 0.001) with little additional graft loss (97.7% vs. 88.1% vs. 85.6). There was no significant difference in patient survival after 5 years (71.7% vs. 67.4% vs 61.9%, P = 0.480). In elderly recipients, the patient survival benefits of an LDK are limited, but there is decreased death-censored graft loss for LDK recipients. Nevertheless, graft survival in ETKAS and ESP remains satisfactory.
AB - Increasing numbers of elderly (>= 65 years) patients are listed for kidney transplantation. This study compares the survival outcome between living (LDK), regularly allocated (ETKAS), and Eurotransplant Senior Program (ESP) donor kidneys in elderly recipients. This is a single-center retrospective cohort study of elderly kidney transplant recipients transplanted between 2005 and 2017. Primary outcome measures were nondeath-censored graft, death-censored graft, and patient survival. In total, 348 patients were transplanted, 109 recipients (31.3%) received an LDK, 100 (28.7%) an ETKAS, and 139 (40%) an ESP kidney. 62.5% were male, and median age was 68 years. LDK recipients had significantly better 5-year nondeath-censored graft survival compared with ETKAS and ESP (resp. 71.0% vs. 66.1% vs. 55.6%, P = 0.047). Death-censored graft survival after 1 year was significantly better in LDK recipients (99.1%) (ETKAS 90.8%; ESP 87.7%, P < 0.001). After 5 years, the difference remained significant (P < 0.001) with little additional graft loss (97.7% vs. 88.1% vs. 85.6). There was no significant difference in patient survival after 5 years (71.7% vs. 67.4% vs 61.9%, P = 0.480). In elderly recipients, the patient survival benefits of an LDK are limited, but there is decreased death-censored graft loss for LDK recipients. Nevertheless, graft survival in ETKAS and ESP remains satisfactory.
KW - deceased donor
KW - elderly patients
KW - graft survival
KW - kidney transplantation
KW - living donor
KW - patient survival
KW - QUALITY-OF-LIFE
KW - KIDNEY-TRANSPLANTATION
KW - GRAFT-SURVIVAL
KW - OLDER
KW - HEMODIALYSIS
KW - PATIENT
KW - AGE
U2 - 10.1111/tri.14130
DO - 10.1111/tri.14130
M3 - Article
C2 - 34626451
SN - 0934-0874
VL - 34
SP - 2746
EP - 2754
JO - Transplant International
JF - Transplant International
IS - 12
ER -